Osteogenon tablets p/o 830 mg No. 10x4

Compound

The core of one Osteogenon tablet contains 830 milligrams of the active ossein-hydroxyapatite compound , which, in turn, consists of collagens (216 mg), non-collagenous proteins and peptides (75 mg), calcium (178 mg), calcium hydrogen phosphate ( hydroxyapatite ) (approximately 444 mg), phosphorus (82 mg), inactive organic fractions (approximately 95 mg).
Among the auxiliary compounds included in the drug are colloidal silicon dioxide, potato starch, microcrystalline cellulose, and magnesium stearate. The drug shell contains hypromellose , titanium dioxide, as well as yellow iron oxide, talc and macrogol.

Osteogenon tablets p/o 830 mg No. 10x4

Name

Osteogenon tablet p/o 830 mg in blister pack No. 10x4

Main active ingredient

Calcium-phosphorus metabolism regulator

Release form

pills

Compound

each coated tablet contains: Active ingredient: ossein-hydroxyapatite compound (OHC) - 830.00 mg (refers to dry substance). The main component of the inorganic part of OGS is calcium phosphate in the form of microcrystalline hydroxyapatite, embedded in the protein matrix. Ossein consists mainly of collagenous and non-collagenous peptides/proteins. Other components: microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, potato starch, hydroxypropyl methylcellulose, titanium dioxide (E171), polyethylene glycol, talc, yellow iron oxide (E172).

Description

film-coated tablets, light yellow, evenly colored, oblong, with biconvex surfaces. Length: ~18.2 mm, width: ~8.7 mm, thickness ~6.2 mm.

Dosage

830mg

pharmachologic effect

Osteogenon has a dual effect on bone metabolism: a stimulating effect on osteoblasts and an inhibitory effect on osteoclasts. Osteogenon contains all the necessary components for the synthesis of bone tissue. Calcium, which is part of the drug, is contained in it in the form of hydroxyapatite (in a 2:1 ratio with phosphorus), which promotes more complete absorption in the gastrointestinal tract: in addition, it inhibits the production of parahormone and prevents hormonally caused resorption of bone tissue. The slow release of calcium from hydroxyapatite results in the absence of a hypercalcemia peak. Phosphorus, which participates in the crystallization of hydroxyapatite, promotes the fixation of calcium in the bone and inhibits its excretion by the kidneys.

Indications for use

- calcium deficiency, especially during the period of growth, pregnancy, lactation; - an additional method of treating osteoporosis, including primary and secondary (senile, postmenopausal, corticosteroid, immobilization during restoration of mobility).

Contraindications

- hypersensitivity to any component; - in patients with severe renal failure and patients on hemodialysis; - hypercalcemia, hypercalciuria, formation of calcium stones, tissue calcification; - prolonged immobilization, accompanied by hypercalcemia and/or hypercalciuria: when treating with calcium, attention should be paid to restoring mobility; - children under 6 years of age in connection with the dosage form.

Directions for use and doses

For oral administration. The tablets should be swallowed with a full glass of water. Adults and children over 6 years of age: - 1-2 tablets per day, corresponding to 178-356 mg elemental calcium/day and 82-164 mg elemental phosphorus/day. For osteoporosis: 2-4 tablets 2 times a day, which corresponds to 356-712 mg of elemental calcium/day and 164-328 mg of elemental phosphorus/day. The duration of treatment is determined by the patient's condition.

Side effect

In rare cases, allergic reactions may occur. Hypercalcemia and hypercalciuria in case of long-term use.

Overdose

Feeling of thirst, polyuria, polydipsia, nausea, vomiting, vasomotor disturbances, constipation.

Interaction with other drugs

Osteogenon slows down the absorption of iron preparations and tetracyclines, therefore, when they are prescribed together, the interval between the time of taking Osteogenon and these drugs should be at least 4 hours.

Precautionary measures

Coadministration of calcium and vitamin D should be closely monitored for serum and urinary calcium levels. In renal failure, high doses should be avoided and serum and urine calcium levels should be regularly monitored. If long-term treatment is required and/or renal impairment is present, calcium levels should be monitored and treatment should be reduced or temporarily discontinued if calcium levels exceed 7.5 mmol/24 hours (300 mg/24 hours) in adults and 0.12 to 0. 15 mmol/kg/24 hours (5-6 mg/kg/24 hours) in children. For patients with moderate renal impairment, monitoring of serum phosphate is recommended.

Storage conditions

Store at a temperature not exceeding 30°C. Keep out of the reach of children.

Pharmacodynamics and pharmacokinetics

Active medicinal compounds contained in Osteogenon function as regulators of phosphorus-calcium metabolism . This drug has found wide use in the treatment and prevention of osteoporosis due to its dual effect on metabolism . On the one hand, the drug stimulates osteoblasts , and on the other, it has an inhibitory effect on osteoclasts .

Due to the content of calcium in the drug in proportion to phosphorus 1:2, the drug promotes the absorption of calcium from the gastrointestinal tract, thereby promoting the production of parathyroid hormone , which, in turn, reduces bone resorption .

The medicine helps slow down the process of calcium release from hydroxyapatite , which blocks the manifestations of hypercalcemia . In addition, phosphorus contained in the chemical composition of the drug is involved in the crystallization of the same hydroxyapatite, which helps slow down the excretion of calcium from the body by the kidneys.

ossein in the drug, bone tissue remodeling occurs. This process inhibits tissue resorption and stimulates bone formation . Osteocalcin contained in the medicinal compound binds calcium, thereby promoting accelerated crystallization of bone tissue, and collagen forms the bone matrix.

Pharmacological properties of the drug Osteogenon

Pharmacodynamics. Regulator of phosphorus-calcium metabolism, which is used for systemic osteoporosis. The drug has a dual effect on bone metabolism: stimulating osteoblasts and inhibiting osteoclasts. These various actions complement each other physiologically and regulate the balance between bone resorption and bone repair. Calcium, which is part of the drug, is contained in the form of hydroxyapatite, which promotes more complete absorption of calcium in the gastrointestinal tract. In addition, it inhibits the synthesis of parathyroid hormone and prevents hormonally mediated bone resorption. The slow release of calcium from hydroxyapatite results in the absence of a hypercalcemia peak. Phosphorus, which participates in the crystallization of hydroxyapatite, promotes the fixation of calcium in the bones and inhibits its excretion by the kidneys. The organic component of the drug (ossein) contains local regulators of bone tissue remodeling (transforming growth factor-beta (β-TGF), insulin-like growth factors I, II (IGF-I, IGF-II), osteocalcin, type I collagen, which activate the process of bone formation . β-TGF stimulates the activity of preosteoblasts, increases their number, promotes collagen formation, and also inhibits the formation of osteoclast precursors. IGF-I and IGF-II stimulate collagen synthesis. Osteocalcin promotes the crystallization of bone tissue by binding calcium. Type I collagen ensures the formation of bone matrix Pharmacokinetics : Absorption occurs at the level of the duodenum and the proximal small intestine.

Indications for use

The drug is recommended for use if:

• osteoporosis of any degree of complexity, including those caused by arthritis , hyperthyroidism , kidney and liver diseases, hyperparathyroidism, as well as immobilization , the use of heparin or corticosteroids;
• osteopenia and imbalance of calcium and phosphorus in the body, including during pregnancy , as well as during breastfeeding ;
• bone fractures , as well as for their speedy healing.

Use of the drug Osteogenon

Inside, with a small amount of water. For systemic osteoporosis, adults are prescribed 2-4 tablets 2 times a day. To accelerate the consolidation of bone fractures - 2 tablets 2-3 times a day. For other indications - 1-2 tablets per day. The duration of treatment for osteoporosis is 6–12 months; for bone fractures, after joint replacement and all other indications - 3 months. The duration of therapy is determined by the doctor depending on the degree of maturity of the callus.

special instructions

People with impaired kidney function should avoid using this drug for a long time.

For patients with a predisposition to urolithiasis , it is vitally important to adhere to a special regimen and dosage of the drug.

Since Osteogenon contains a trace amount of sodium chloride in its chemical composition, the drug is approved for use in the treatment of patients who suffer from arterial hypertension .

The drug does not affect the ability to drive vehicles.

Osteogenon 830 mg No. 40 tablet p.p.o.

Instructions for medical use of the drug Osteogenon Trade name Osteogenon International nonproprietary name No Dosage form Film-coated tablets, 830 mg Composition One tablet contains the active substance: ossein hydroxyapathic compound 830 mg (corresponding to non-collagen proteins/peptides 75 mg, collagen proteins/peptides 216 mg, calcium 178 mg and phosphorus 82 mg) excipients: potato starch, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate shell composition: hydroxypropyl methylcellulose, polyethylene glycol, talc, titanium dioxide E171, iron (III) yellow oxide E172 Description Oblong tablets with a biconvex surface , covered with a light yellow shell, at the fracture there is a light gray core. Pharmacotherapeutic group Drugs for the treatment of bone diseases. Other drugs that affect bone structure and mineralization. ATC code M05BX Pharmacological properties Pharmacokinetics Studies conducted on humans using isotopes (Ca47) showed excellent absorption of the drug in the intestine. Compared to simple calcium salts, Osteogenon did not create peaks of hypercalcemia; this is explained by the slower absorption of ossein - hydroxyapatite complex in the intestine, as well as its continuous absorption. For this reason, slow dissolution of the complex leads to better distal absorption of calcium. Pharmacodynamics Osteogenon contains organic bone tissue components (ossein) and a mineral bone component (microcrystalline hydroxyapatite), consisting of calcium and phosphorus in a naturally balanced ratio. Ossein contains collagen and non-collagen peptides that have a positive effect on the formation of bone tissue. Indications for use - osteoporosis of various origins - acceleration of healing of bone fractures - correction of osteopenia and regulation of calcium-phosphorus balance during pregnancy and lactation. Method of administration and dosage Osteogenon is prescribed to adults. — for osteoporosis: 2-4 tablets 2 times a day; — when correcting the calcium-phosphorus balance during pregnancy and breastfeeding: 1-2 tablets per day; - concomitant treatment of fractures in adults: 2 tablets 3 times a day; The tablets are swallowed with a small amount of water. The duration of treatment depends on the diagnosis and is determined by the doctor. Side effects Like all medicines, Osteogenon can cause side effects, although not everyone gets them. The following side effects have been found, although the exact frequency of occurrence cannot be determined and therefore they are classified as having an unknown frequency of manifestations: - long-term treatment with high dosages of the drug may increase the concentration of calcium in the blood or urine (hypercalcemia and hypercalciuria) - abdominal pain , constipation, nausea - itching, rash Contraindications - hypersensitivity to the components of the drug - hypercalcemia, hypercalciuria - calcium lithiasis - prolonged immobilization - children under 18 years of age - patients with severe renal failure and patients on hemodialysis Drug interactions With the concomitant prescription of certain tetracycline antibiotics a number of or iron-containing drugs Osteogenon may reduce their absorption. For this reason, you should not take the above drugs at the same time and the interval between taking these drugs and Osteogenon should be at least 4 hours. Combined use with cardiac glycosides causes cardiac arrhythmia. An interval between doses of drugs of at least 4 hours should be observed. When taken together with bisphosphonates, there is a possible risk of decreased intestinal absorption of the latter. It is recommended to take Osteogenon 4 hours after taking bisphosphonates. Thiazide diuretics - there may be a risk of hypercalcemia as a result of decreased urinary calcium excretion. Special instructions When taking Osteogenon, calcium and vitamin D drugs in combination, patients should be monitored for hypercalcemia and hypercalciuria. In patients with high concentrations of calcium in the blood and urine, the dosage regimen should be adjusted. In patients at high risk of urolithiasis, as well as in patients suffering from renal diseases, dose adjustment is necessary and long-term use of Osteogenon should be avoided. In patients suffering from renal failure, it is necessary to regularly monitor the level of calcium in the blood and urine, and should also avoid taking Osteogenon in high doses. In case of long-term therapy and/or renal impairment, it is necessary to check the level of calcium in the blood and if it exceeds 7.5 mmol/24 hours (300 mg/24 hours) in adults and from 0.12 to 0.15 mmol/24 hours in children, the dose should be reduced drug or temporarily suspend treatment. In patients suffering from moderate renal impairment, it is recommended to monitor serum phosphorus levels. Pregnancy and lactation The results of clinical studies conducted in pregnant women did not show any risk to the fetus. The drug can be used during pregnancy and breastfeeding after consulting a doctor. Features of the effect on the ability to drive vehicles and potentially dangerous mechanisms The drug does not affect the ability to drive vehicles and operate machinery. Overdose Symptoms - nausea, vomiting, polyuria, thirst, dehydration, arterial hypertension, vasomotor disorders, constipation. Treatment - it is necessary to stop taking all calcium-containing drugs, including vitamin D. Depending on the stage of intoxication, rehydration therapy (restoration of water-salt balance), diuretics, corticosteroids, calcitonin, possibly in combination with peritoneal dialysis, are prescribed together or separately. Release form and packaging 10 tablets are placed in a blister pack made of PVC/PVDC and aluminum foil. 4 contour packages together with instructions for medical use in the state and Russian languages ​​are placed in a cardboard box. Storage conditions Store at a temperature not exceeding 30 ºС. Keep out of the reach of children! Shelf life: 4 years Do not use after expiration date. Conditions for dispensing from pharmacies By prescription Manufacturer Pierre Fabre Medicine Production Etablissement Progipharm Rue du Lucee 45500 Gien, France (Progipharm) st. Liss, 45500 Gien, France Registration certificate holder Pierre Fabre Medicine PIERRE FABRE MEDICAMENT 45, Place Abel Gance, France Address of the organization, accepting claims from consumers on the quality of products (products) on the territory of the Republic of Kazakhstan Representative office of “EUROMEDEX” 050009, Almaty, 155 Abay Ave., office 37 Tel./Fax e-mail

Osteogenon analogues

Level 4 ATX code matches:
Prolia

Osteocea

Bivalos

At the moment, no analogues of Osteogenon can be found on the open market. This means that there are no drugs with a similar chemical composition, which, like this drug, will affect the course of mineralization of bone tissue and act as a regulator of phosphorus-calcium metabolism in the body. However, the attending physician can always select a drug that is similar in action and which will contain other active compounds.

Reviews about Osteogenon

Most reviews of Osteogenon for fractures are positive. We can say that doctors most often prescribe this drug for bone tissue damage of varying severity. People who have taken the drug note that it does not cause side effects and helps in the prevention and treatment of various diseases associated with damage to bone tissue, including osteoporosis .

calcium deficiency , respond well to the drug . Reviews from doctors about Osteogenon can be called more than “cool”. Many doctors are truly skeptical about this drug and its ability to influence the regeneration of bone tissue, and therefore express rather contradictory opinions that diverge from the assurances of the drug’s manufacturers.

However, the number of doctors prescribing Osteogenon as a stimulator of bone tissue mineralization is also large, especially since the effectiveness of the drug in each specific case may vary. Therefore, if you have doubts about the strength of the drug's medicinal effect, it is advisable to study the condition of bone tissue using x-rays , as well as urine and blood tests to determine the calcium content in biological fluids.

Osteogenon price, where to buy

The average price of Osteogenon (a package with a nominal volume of 800 milligrams containing 40 tablets) will vary between 550-600 rubles.

• Online pharmacies in RussiaRussia
• Online pharmacies in UkraineUkraine
• Online pharmacies in KazakhstanKazakhstan

ZdravCity

• Osteogenon tab.
  p/o 830 mg 40 pcs Pierre Fabre 758 RUR order

Pharmacy Dialogue

• Osteogenon (tablet p/o 830 mg No. 40)Pierre Fabre Medicament

  RUR 762 order

show more

Pharmacy24

• Osteogenon No. 40 tablets Pierre Fabre Medicine Production, France
  456 UAH.order

PaniPharmacy

• Osteogenon tablets Osteogenon tablets No. 40 France, Pierre Fabre Medicament Production

  467 UAH order

show more